JP2022088642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022088642A5 JP2022088642A5 JP2022063285A JP2022063285A JP2022088642A5 JP 2022088642 A5 JP2022088642 A5 JP 2022088642A5 JP 2022063285 A JP2022063285 A JP 2022063285A JP 2022063285 A JP2022063285 A JP 2022063285A JP 2022088642 A5 JP2022088642 A5 JP 2022088642A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- injury
- condition
- stroke
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025031851A JP2025084908A (ja) | 2016-04-21 | 2025-02-28 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325860P | 2016-04-21 | 2016-04-21 | |
| US62/325,860 | 2016-04-21 | ||
| JP2018555672A JP7109005B2 (ja) | 2016-04-21 | 2017-04-21 | 神経学的状態および心血管状態を処置するための化合物および方法 |
| PCT/US2017/028996 WO2017185061A1 (en) | 2016-04-21 | 2017-04-21 | Compounds and methods for treating neurological and cardiovascular conditions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555672A Division JP7109005B2 (ja) | 2016-04-21 | 2017-04-21 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025031851A Division JP2025084908A (ja) | 2016-04-21 | 2025-02-28 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022088642A JP2022088642A (ja) | 2022-06-14 |
| JP2022088642A5 true JP2022088642A5 (enExample) | 2022-12-21 |
| JP7709141B2 JP7709141B2 (ja) | 2025-07-16 |
Family
ID=60022855
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555672A Active JP7109005B2 (ja) | 2016-04-21 | 2017-04-21 | 神経学的状態および心血管状態を処置するための化合物および方法 |
| JP2022063285A Active JP7709141B2 (ja) | 2016-04-21 | 2022-04-06 | 神経学的状態および心血管状態を処置するための化合物および方法 |
| JP2025031851A Pending JP2025084908A (ja) | 2016-04-21 | 2025-02-28 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555672A Active JP7109005B2 (ja) | 2016-04-21 | 2017-04-21 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025031851A Pending JP2025084908A (ja) | 2016-04-21 | 2025-02-28 | 神経学的状態および心血管状態を処置するための化合物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US12239654B2 (enExample) |
| EP (2) | EP3445368B1 (enExample) |
| JP (3) | JP7109005B2 (enExample) |
| KR (2) | KR20220132042A (enExample) |
| CN (2) | CN109310695B (enExample) |
| AU (2) | AU2017254720B2 (enExample) |
| CA (1) | CA3020490A1 (enExample) |
| EA (1) | EA201892008A1 (enExample) |
| ES (1) | ES2989621T3 (enExample) |
| IL (2) | IL289423B2 (enExample) |
| MX (1) | MX391725B (enExample) |
| WO (1) | WO2017185061A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA120628C2 (uk) | 2014-11-07 | 2020-01-10 | Басф Се | Пестицидні суміші |
| US11241012B2 (en) | 2016-03-16 | 2022-02-08 | Basf Se | Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean |
| CA3015456C (en) | 2016-03-16 | 2024-09-17 | Basf Se | USE OF TETRAZOLINONES TO CONTROL RESISTANT PLANT PATHOGENIC FUNGI ON FRUIT |
| ES3056157T3 (en) | 2016-03-16 | 2026-02-18 | Basf Se | Use of a specific tetrazolinone for combating resistant phytopathogenic fungi on cereals |
| EP3445368B1 (en) | 2016-04-21 | 2024-07-17 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| CN112218638A (zh) * | 2018-02-09 | 2021-01-12 | 阿斯特罗赛特制药公司 | 用于治疗成瘾和相关病症的化合物和方法 |
| WO2019232554A2 (en) * | 2018-05-26 | 2019-12-05 | Primetime Life Sciences, Llc | Compounds and methods for modulation of g-protein-coupled receptors |
| WO2020061211A1 (en) * | 2018-09-18 | 2020-03-26 | Saint Louis University | Use of highly-selective adenosine 3a receptor subtype agonists |
| EP3856741A4 (en) | 2018-09-26 | 2022-06-22 | Astrocyte Pharmaceuticals, Inc. | POLYMORPHOUS COMPOUNDS AND USES THEREOF |
| JP7282324B2 (ja) * | 2018-12-11 | 2023-05-29 | 株式会社島津製作所 | イオン化装置、質量分析装置および流体試料の分析方法 |
| WO2020176544A1 (en) * | 2019-02-25 | 2020-09-03 | Saint Louis University | Treatment of alzheimer's disease |
| JOP20210296A1 (ar) * | 2019-05-06 | 2023-01-30 | Ferrer Int | صور جرعة صلبة صيدلية أو دوائية مغذية متعددة الطبقات ومشتملة على مشتقات بيريميدين و/أو بيورين وفيتامينات ب، وتحضيرها واستخداماتها |
| IL307967A (en) * | 2021-04-28 | 2023-12-01 | Astrocyte Pharmaceuticals Inc | Purine nucleosides, their intermediates and methods for their preparation |
| KR20240122782A (ko) * | 2021-11-22 | 2024-08-13 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경학적 및 심혈관 상태를 치료하는 방법 |
| CA3250090A1 (en) * | 2022-02-10 | 2023-08-17 | Academia Sinica | METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION |
| WO2024097387A1 (en) * | 2022-11-03 | 2024-05-10 | Astrocyte Pharmaceuticals, Inc. | Compositions for intravenous administration |
| WO2024144874A2 (en) * | 2022-11-03 | 2024-07-04 | Astrocyte Pharmaceuticals, Inc. | Fast-dissolving dosage forms and uses thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995002604A1 (en) | 1993-07-13 | 1995-01-26 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| US7348315B2 (en) | 1995-03-23 | 2008-03-25 | The University Of Connecticut | Methods of treating heart failure with modified ATP, ADP and AMP compounds |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US6586413B2 (en) | 1999-11-05 | 2003-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| EP1248869A2 (en) | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| US7087589B2 (en) | 2000-01-14 | 2006-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methanocarba cycloakyl nucleoside analogues |
| US7589075B2 (en) | 2001-01-16 | 2009-09-15 | Can-Fite Biopharma Ltd. | Use of an adenosine A3 receptor agonist for inhibition of viral replication |
| WO2003051881A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| GB0209539D0 (en) | 2002-04-26 | 2002-06-05 | Avecia Ltd | Monomer Polymer and process |
| EP2410332A1 (en) | 2002-11-21 | 2012-01-25 | The University Of Utah | Method for identifying purinergic modulators of the olfactory system |
| JP2007517019A (ja) * | 2003-12-29 | 2007-06-28 | カン−フィテ・バイオファーマ・リミテッド | 多発性硬化症の治療方法 |
| GB0405009D0 (en) * | 2004-03-05 | 2004-04-07 | Cambridge Biotechnology Ltd | Analgesics |
| JP2008512457A (ja) | 2004-09-09 | 2008-04-24 | アメリカ合衆国 | Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体 |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| WO2007020018A1 (en) | 2005-08-12 | 2007-02-22 | Universite Libre De Bruxelles | Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| EP2049127B1 (en) | 2006-05-23 | 2014-11-26 | University of Connecticut | N-methanocarba derivatives to treat cardiac diseases |
| WO2008021552A2 (en) | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
| US20100047798A1 (en) | 2006-11-08 | 2010-02-25 | Thomas Jefferson University | Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome |
| US7867983B2 (en) | 2007-03-29 | 2011-01-11 | The University Of Connecticut | Methods to protect skeletal muscle against injury |
| US20090088403A1 (en) | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| WO2009010871A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as antagonists of adenosine a3 receptor |
| DE102007055529A1 (de) | 2007-08-06 | 2009-02-12 | Rhode & Schwarz Gmbh & Co. Kg | Verfahren und Anordnung zum Erzeugen eines frequenzmodulierten Signals |
| JP5592262B2 (ja) | 2007-10-15 | 2014-09-17 | キャン−ファイト・バイオファーマ・リミテッド | 肝細胞の増殖を誘導する方法及びその使用 |
| BRPI0818578A2 (pt) | 2007-10-17 | 2015-07-21 | Novartis Ag | Derivados de purina como ligantes receptores de adenosina a1 |
| CN101925610A (zh) | 2007-11-23 | 2010-12-22 | 巴尔-伊兰大学 | 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途 |
| AU2009231978C1 (en) | 2008-03-31 | 2014-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as A3 adenosine receptor- selective agonists |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| US8399018B2 (en) | 2008-07-21 | 2013-03-19 | Otonomy, Inc. | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| EP2331542B1 (en) | 2008-08-01 | 2016-07-27 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | A3 adenosine receptor antagonists and partial agonists |
| US8685372B2 (en) | 2009-04-15 | 2014-04-01 | The Regents Of The University Of California | Peptides and aptamers for targeting of neuron or nerves |
| US8518957B2 (en) | 2009-12-02 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure |
| WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
| US8822434B2 (en) | 2010-02-22 | 2014-09-02 | The University Of Connecticut | Compositions and methods to treat cardiac diseases |
| US8691775B2 (en) | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
| US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
| US20140241990A1 (en) | 2011-09-30 | 2014-08-28 | Tufts University | Methods of using adenosine a1 receptor activation for treating depression |
| SI2968385T1 (sl) | 2013-03-13 | 2018-10-30 | Tufts University | Uridin nukleozid derivati, sestavki in metode uporabe |
| US20150087613A1 (en) | 2013-09-26 | 2015-03-26 | Saint Louis University | Inhibition of Opioid Antinociceptive Tolerance and Withdrawal in Nociceptive Pain Therapy |
| US9963450B2 (en) | 2013-11-27 | 2018-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists |
| US20160024135A1 (en) | 2014-07-27 | 2016-01-28 | Zhejiang Subtropical Crops Research Institute | Adenosine receptor activation reagent and the uses of thereof |
| HK1247119A1 (zh) | 2015-02-04 | 2018-09-21 | 贝克心脏与糖尿病研究所 | 一种治疗方法和用於所述治疗方法中的化合物 |
| RU2017129539A (ru) | 2015-02-24 | 2019-03-25 | Гальвани Байоэлектроникс Лимитед | Устройство нейромодуляции |
| CN108685935B (zh) * | 2015-05-06 | 2019-10-11 | 浙江省亚热带作物研究所 | 一种含有腺苷受体激动试剂的食品 |
| EP3445368B1 (en) | 2016-04-21 | 2024-07-17 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
| US10683292B2 (en) | 2016-07-25 | 2020-06-16 | Nerviano Medical Sciences S.R.L. | Purine and 3-deazapurine analogues as choline kinase inhibitors |
| CN109666053A (zh) * | 2017-10-16 | 2019-04-23 | 张家口华健致远生物科技有限公司 | 一种a3腺苷受体激动剂及其用途 |
| CN112218638A (zh) | 2018-02-09 | 2021-01-12 | 阿斯特罗赛特制药公司 | 用于治疗成瘾和相关病症的化合物和方法 |
| KR102602990B1 (ko) | 2018-06-27 | 2023-11-17 | 에스케이하이닉스 주식회사 | 전원 공급 장치 및 이를 포함하는 전자 장치 |
| EP3856741A4 (en) | 2018-09-26 | 2022-06-22 | Astrocyte Pharmaceuticals, Inc. | POLYMORPHOUS COMPOUNDS AND USES THEREOF |
| CA3146679A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| IL307967A (en) | 2021-04-28 | 2023-12-01 | Astrocyte Pharmaceuticals Inc | Purine nucleosides, their intermediates and methods for their preparation |
| KR20240122782A (ko) | 2021-11-22 | 2024-08-13 | 아스트로사이트 파마슈티컬스, 인코포레이티드 | 신경학적 및 심혈관 상태를 치료하는 방법 |
-
2017
- 2017-04-21 EP EP17786774.4A patent/EP3445368B1/en active Active
- 2017-04-21 KR KR1020227032219A patent/KR20220132042A/ko not_active Ceased
- 2017-04-21 ES ES17786774T patent/ES2989621T3/es active Active
- 2017-04-21 CN CN201780024816.XA patent/CN109310695B/zh active Active
- 2017-04-21 US US16/095,282 patent/US12239654B2/en active Active
- 2017-04-21 JP JP2018555672A patent/JP7109005B2/ja active Active
- 2017-04-21 AU AU2017254720A patent/AU2017254720B2/en active Active
- 2017-04-21 CN CN202210281874.3A patent/CN114903903A/zh active Pending
- 2017-04-21 MX MX2018012655A patent/MX391725B/es unknown
- 2017-04-21 EA EA201892008A patent/EA201892008A1/ru unknown
- 2017-04-21 CA CA3020490A patent/CA3020490A1/en active Pending
- 2017-04-21 WO PCT/US2017/028996 patent/WO2017185061A1/en not_active Ceased
- 2017-04-21 IL IL289423A patent/IL289423B2/en unknown
- 2017-04-21 US US15/494,407 patent/US9789131B1/en active Active
- 2017-04-21 EP EP24184468.7A patent/EP4414027A3/en active Pending
- 2017-04-21 KR KR1020187033797A patent/KR102445887B1/ko active Active
- 2017-08-07 US US15/670,738 patent/US10265338B2/en active Active
-
2018
- 2018-10-21 IL IL262487A patent/IL262487B/en unknown
-
2019
- 2019-03-14 US US16/353,737 patent/US10953031B2/en active Active
-
2021
- 2021-02-19 US US17/180,469 patent/US11484545B2/en active Active
-
2022
- 2022-04-06 JP JP2022063285A patent/JP7709141B2/ja active Active
- 2022-09-21 US US17/934,169 patent/US12390483B2/en active Active
-
2023
- 2023-05-02 AU AU2023202694A patent/AU2023202694B2/en active Active
-
2025
- 2025-02-28 JP JP2025031851A patent/JP2025084908A/ja active Pending
- 2025-07-17 US US19/272,745 patent/US20250345353A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022088642A5 (enExample) | ||
| JP2022502405A5 (enExample) | ||
| US20230012655A1 (en) | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | |
| JP2019515920A5 (enExample) | ||
| US8415352B2 (en) | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | |
| Tatton et al. | Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation | |
| CA2904180C (en) | Uridine nucleoside derivatives, compositions and methods of use | |
| JP6162125B2 (ja) | 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法 | |
| CN103533835A (zh) | S1p调节剂 | |
| CN1178914C (zh) | 4-苄基-1-[2-(4-羟基-苯氧基)乙基]-哌啶-3,4-二醇 | |
| TW201026667A (en) | Glycine b antagonists | |
| JP2022531144A (ja) | 神経疾患又は精神疾患を治療するためのＫｖ３カリウムチャネル活性化薬としてのＮ－（（ヘテロアリール）メチル）－１－トシル－１Ｈ－ピラゾール－３－カルボキサミド誘導体 | |
| CN105829300A (zh) | 作为pde1抑制剂的喹唑啉-thf-胺 | |
| US20140371167A1 (en) | Uridine nucleoside derivatives, compositions and methods of use | |
| JP2022509416A (ja) | Ｋｖ３カリウムチャネル活性化薬としてのアリールスルホニルピロールカルボキサミド誘導体 | |
| JP2003535821A (ja) | 緑内障を治療するための５−ヒドロキシインダゾール誘導体 | |
| WO2019189781A1 (ja) | 神経細胞内カルシウム濃度上昇抑制剤 | |
| JPH09511526A (ja) | 治療に有用なキノキサリン誘導体 | |
| US20200040025A1 (en) | Uridine nucleoside derivatives, compositions and methods of use | |
| JP2016513677A5 (enExample) | ||
| RU2015144155A (ru) | Мускариновые агонисты | |
| DS | Down syndrome cell adhesion molecule–a common determinant of brain and heart wiring | |
| NZ747047A (en) | Compounds and methods for treating neurological and cardiovascular conditions | |
| WO2011147780A1 (en) | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | |
| NZ747047B2 (en) | Compounds and methods for treating neurological and cardiovascular conditions |